Follicular Lymphoma Treatment Market 2026 projected to reach $4.91 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Follicular Lymphoma Treatment Market Over The Period 2026–2030?

The follicular lymphoma treatment market has experienced robust expansion in recent years. It is projected to increase from $3.28 billion in 2025 to $3.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. The market’s past growth is attributable to advancements in monoclonal antibodies, heightened awareness of lymphoma, the proliferation of oncology research, improvements in hospital infrastructure, and a rising incidence of non-Hodgkin lymphoma.

The follicular lymphoma treatment market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $4.91 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth over the forecast period is attributable to several factors, including advancements in targeted therapy, the incorporation of AI into treatment planning, an increase in stem cell transplant procedures, the proliferation of oncology centers in emerging markets, and the creation of biosimilars. Key trends shaping the forecast period encompass tailored treatment protocols, the emergence of novel monoclonal antibodies, the adoption of combination therapy strategies, intensified early diagnosis and screening efforts, and the application of minimally invasive treatment techniques.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10758&type=smp

Which Major Factors Are Driving The Expansion Of The Follicular Lymphoma Treatment Market?

The increasing prevalence of follicular lymphoma is anticipated to propel the growth of the follicular lymphoma treatment market. The prevalence of follicular lymphoma refers to the total number or proportion of individuals diagnosed with the condition within a specific population over a given time or period. This rise is attributed to an aging population, genetic predisposition, improved diagnostic techniques, and increased awareness and screening efforts. Follicular lymphoma treatment helps mitigate its prevalence by addressing the disease at various stages, thereby aiding in disease management and hindering progression. A growing incidence of follicular lymphoma is further boosting the follicular lymphoma treatment market’s expansion. For instance, in January 2023, the American Cancer Society, a US-based voluntary organization, stated that non-Hodgkin lymphoma, which includes indolent follicular lymphoma, is the most common cancer in the US, accounting for approximately 4% of all cancers. The American Cancer Society projects that approximately 80,550 individuals (44,880 men and 35,670 women), including both adults and children, will be diagnosed with NHL. Consequently, the rising prevalence of follicular lymphoma is a primary driver for the growth of the follicular lymphoma treatment market.

How Is The Follicular Lymphoma Treatment Market Divided Into Its Major Segments?

The follicular lymphoma treatment market covered in this report is segmented –

1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents

2) By Product Type: Tablets, Capsules, Injectables, Other Product Types

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Rituximab, Obinutuzumab, Ofatumumab

2) By Targeted Therapy: PI3K Inhibitors, BTK Inhibitors, BCL-2 Inhibitors

3) By Chemotherapy: CHOP Regimen, Bendamustine, Fludarabine

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioimmunotherapy

5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant

6) By Alkylating Agents: Cyclophosphamide, Ifosfamide

How Are Trends Transforming The Follicular Lymphoma Treatment Market Landscape?

Major companies operating in the follicular lymphoma treatment market are concentrating on developing advanced solutions, such as bispecific antibodies, to enhance durable remission and reduce patient treatment burden. A bispecific antibody is an engineered molecule designed to simultaneously bind two distinct targets; for example, one arm attaches to a tumor antigen on B cells while the other engages T cells, thereby redirecting the immune system to kill cancer cells more efficiently. For instance, in March 2025, Chugai Pharmaceutical, a Japan-based research-driven oncology company, launched LUNSUMIO, which features a CD20/CD3 bispecific antibody system. LUNSUMIO is approved as an intravenous infusion in 1 mg and 30 mg formulations. It is intended for patients with relapsed or refractory follicular lymphoma who have failed at least two prior standard therapies. This therapy is designed for fixed-duration treatment based on individual patient response, which can reduce long-term treatment burden. LUNSUMIO has demonstrated high complete response rates and has the potential to deliver durable remission as a monotherapy.

Who Are The Prominent Organizations Shaping The Follicular Lymphoma Treatment Market?

Major companies operating in the follicular lymphoma treatment market are AbbVie Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson and Johnson Services Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Boehringer Ingelheim GmbH, CTI BioPharma Corp., Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Daiichi Sankyo Company Ltd., Pfizer Inc., Incyte Corporation, MorphoSys AG, Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Seagen Inc., Takeda Pharmaceutical Company, Nordic Nanovector ASA, ADC Therapeutics SA, MEI Pharma Inc., BeiGene Inc., TG Therapeutics Inc., Amgen Inc.

Read the full follicular lymphoma treatment market report here:

https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Follicular Lymphoma Treatment Market?

North America was the largest region in the follicular lymphoma treatment market in 2025. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Follicular Lymphoma Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10758&type=smp

Browse Through More Reports Similar to the Global Follicular Lymphoma Treatment Market 2026, By The Business Research Company

Follicular Lymphoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report

Emphysema Market Report 2026

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Diffuse Large B Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795